A pharma C-suite shakeup and Trump’s deal with Pfizer

How will we look back on Emma Walmsley’s tenure as GSK’s CEO? Why did one of the FDA’s top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff?

We discuss all that and more on this week’s episode of “The Readout LOUD,” a weekly biotech podcast from STAT.